Amneal to Report Third Quarter 2025 Results on October 30, 2025
Rhea-AI Summary
Amneal Pharmaceuticals (NASDAQ: AMRX), a global biopharmaceutical company, has scheduled its third quarter 2025 financial results announcement for Thursday, October 30, 2025, before market open.
The company will host an audio webcast at 8:30 a.m. ET accessible through their Investor Relations website. Participants can join via webcast or dial in using 1 (833) 470-1428 in the U.S. with access code 272787. International toll-free numbers are available, and a replay will be provided after the call.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, AMRX gained 3.70%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
BRIDGEWATER, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that the Company will release its third quarter 2025 financial results on Thursday, October 30, 2025, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET.
The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. Individuals may register for the webcast by clicking the link here. To access the call through a conference line, dial 1 (833) 470-1428 (in the U.S.) or for a list of toll-free international numbers, visit this here. The access code for the call is 272787. A replay of the conference call will be posted shortly after the call.
About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceutical company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 280 pharmaceuticals, primarily within the United States. In its Affordable Medicines segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com and follow us on LinkedIn.
Investor Contact
Anthony DiMeo
VP, Investor Relations
anthony.dimeo@amneal.com
FAQ
When will Amneal Pharmaceuticals (AMRX) report Q3 2025 earnings?
How can investors access Amneal's Q3 2025 earnings call?
Where can I find the replay of Amneal's Q3 2025 earnings call?
What time is Amneal's Q3 2025 earnings call?
